Sign up UNITED KINGDOM
Proactive Investors - Run By Investors For Investors
Why invest in VAL?
ValiRx Plc: THE INVESTMENT CASE

Valirx's talks in lung cancer highlight progress on all fronts

Valirx raised just short of a £1mln in May to progress the clinical trial of VAL201 and to advance the pre-clinical programmes, VAL101 and VAL301.
cancer
INVESTMENT OVERVIEW: VAL The Big Picture
Valirx is focused on cancer treatments

ValiRx Plc’s (LON:VAL) has made notable progress across its portfolio over the past twelve months.

In June, the biotech said “advanced conversations” were underway with possible partners as it looked to press ahead with the development of its VAL401 lung cancer candidate.

Earlier this year, the AIM-quoted firm released the results from a phase II trial which confirmed that the drug had a “statistically significant” improvement in overall survival for patients with non-small cell lung cancer compared to those receiving no treatment.

The data also showed that VAL401 had a “measurable improvement” on a patient’s quality of life.

Since then, ValiRx has been further analysing the results and discussing them with various industry opinion leaders and oncology specialists.

Suzy Dilly, the chief executive of ValiSeek – the joint venture company which has developed VAL401 –  also attended the BIO International Convention in Boston in June where she met with potential partners to discuss possible partnerships.

“The external validation from both the Advisory Board and wider industry, has provided increased confidence that VAL401, the product, has a valued and needed place in the market,” said Dilly.

Prostate dosing

Valirx's prostate cancer treatment, VAL201, has also been cleared for a much higher dose to be tested after a phase I/II clinical trial in men with prostate cancer went well.

The change to the Phase I/II dose escalation study will help ValiRx assess the stage in the cancer’s progression at which VAL201 is most effective.

This, in turn, will allow the drug developer to plan “larger, outcome-oriented clinical trials”.

Again, Valirx will seek a partner to help fund a much larger study of the cancer treatment.

Elsewhere, an optimised version of the VAL101 compound was found to be effective in inducing programmed cell death in cancer cell models, a process called apoptosis.

The company said the results showed a “superior apoptotic effect in comparison to currently available reagents”.

Finally, VAL301 is in late pre-clinical phase initially for the treatment of the gynaecological condition, endometriosis

Cash raised

As a result of the programmes it is working on, Valirx is still burning through a decent amount of cash and raised just short of a £1mln in May to progress the clinical trial of VAL201 and to advance the pre-clinical programmes, VAL101 and VAL301.

Shares were issued in the placing at 2p and have since risen to 2.5p.

 

View full VAL profile View Profile

ValiRx Plc Timeline

Related Articles

Drug discovery
April 04 2018
In the group’s 2017 results statement at the end of March, Ray Barlow - who took over as CEO on 6 April 2017 - commented: “We are now focused on the right activities"
researcher filling a vial
May 29 2018
ImmuPharma chairman Tim McCarthy said: "We continue to believe Lupuzor has the potential to bring a much needed treatment to Lupus sufferers around the world"
Skin beauty
April 19 2018
In a note to clients initiating coverage on SkinBio, the joint ‘house’ broker noted that, as the skin microbiome group operates in a new therapeutic area, there is little market data in the sector

No investment advice

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value or suitability of any particular security, portfolio of securities, transaction, investment strategy, or other matter.

You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including company related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

© Proactive Investors 2018

Proactive Investors Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use